Holen Sie sich die Stockscreener-App
30.78
0.06%
-0.02
Handel nachbörslich:
30.78
Edgewise Therapeutics Inc Aktie (EWTX) Neueste Nachrichten
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Purchased by State Street Corp - MarketBeat
What is Leerink Partnrs’ Forecast for EWTX FY2026 Earnings? - Defense World
Leerink Partnrs Has Strong Estimate for EWTX FY2026 Earnings - MarketBeat
EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study - MSN
Short Interest in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Decreases By 10.2% - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of “Buy” by Analysts - Defense World
Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Expected to Rise, Evercore ISI Analyst Says - MarketBeat
EWTX Stock Rises On Upbeat Data From Rare Muscular Disorder Study - Barchart
Wellington Management Group LLP Sells 288,526 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease - AOL
Edgewise Therapeutics' SWOT analysis: stock poised for growth amid clinical milestones - Investing.com
Edgewise Therapeutics (NASDAQ:EWTX) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Edgewise weighs fast approval path for muscular dystrophy drug - BioPharma Dive
Edgewise Therapeutics (EWTX) Stock Jumps After Positive Trial News - Stocks Telegraph
Edgewise Therapeutics Shares Higher on Positive Trial Results - MarketWatch
Edgewise rises on mid-stage trial results for muscular dystrophy candidate - Seeking Alpha
Edgewise Therapeutics Shares Surge 21% on Positive Phase 2 CANYON Trial Results for Becker Muscular Dystrophy Drug - mediahousepress
Edgewise Therapeutics shares surge on positive trial results By Investing.com - Investing.com Australia
Edgewise Therapeutics shares surge on positive trial results - Investing.com India
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket - Benzinga
Edgewise's Muscular Dystrophy Drug Shows Promising 28% Reduction in Muscle Damage in Phase 2 Trial - StockTitan
Trading (EWTX) With Integrated Risk Controls - Stock Traders Daily
Edgewise distances from researcher criticized by FDA - BizWest
28,303 Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Bought by XTX Topco Ltd - MarketBeat
Hypertrophic Cardiomyopathy Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Edgewise Therapeutics, Novartis, Lexicon Pharma, Shandong Suncadia Medicine, Ji Xing Pharma - Barchart
Hypertrophic Cardiomyopathy Market Forecasted to Surge - openPR
Fmr LLC Sells 4,127,355 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Sold by Frazier Life Sciences Management L.P. - MarketBeat
Charles Schwab Investment Management Inc. Sells 49,111 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Data-Based Insights About Edgewise Therapeutics Inc (EWTX) - Stocks Register
Edgewise confirms FDA compliance amid warning to researcher By Investing.com - Investing.com Canada
Truist maintains Buy on Edgewise Therapeutics, holds $50 target By Investing.com - Investing.com Canada
Edgewise confirms FDA compliance amid warning to researcher - Investing.com
Edgewise Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease Research - Business Wire
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Sold by Polar Asset Management Partners Inc. - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Stock Holdings Lifted by Janus Henderson Group PLC - MarketBeat
Glenmede Trust Co. NA Makes New Investment in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics' SWOT analysis: biotech stock poised for growth amid clinical milestones - Investing.com Australia
Parkman Healthcare Partners LLC Has $17.54 Million Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
How the (EWTX) price action is used to our Advantage - Stock Traders Daily
HighVista Strategies LLC Makes New $2.37 Million Investment in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
21,128 Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Bought by Fred Alger Management LLC - MarketBeat
19,900 Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Acquired by Intech Investment Management LLC - MarketBeat
Walleye Capital LLC Purchases New Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Braidwell LP Purchases Shares of 1,958,310 Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Expected to Rise, Truist Financial Analyst Says - Defense World
Ally Bridge Group NY LLC Buys Shares of 187,695 Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Acuta Capital Partners LLC Buys Shares of 63,000 Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics shares target lifted, buy rating on positive outlook By Investing.com - Investing.com UK
Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024 - BioSpace
Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation - Simply Wall St
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):